Longeveron (LGVN) risk factors

Item 1A of every Longeveron Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open LGVN in Gloom →

Longeveron's chart, financials and news, free in your browser.Open LGVN in Gloom →

FY2025 10-K risk factors
96 risks21 new17 dropped30 reworded
Longeveron faces concentrated risks around its lead bone marrow-derived cell therapy, laromestrocel, and Alzheimer's disease development.
Filed Mar 17, 2026
FY2024 10-K risk factors
92 risks
Longeveron relies on unproven stem cell technologies with no approved products and ongoing going concern uncertainty.
Filed Feb 28, 2025